Wood-Smoke Exposure as a Response and Survival Predictor in Erlotinib-treated Non-small Cell Lung Cancer Patients: An Open Label Phase II Study
Open Access
- 1 August 2008
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 3 (8) , 887-893
- https://doi.org/10.1097/jto.0b013e31818026f6
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Pharmacogenomic and Pharmacokinetic Determinants of Erlotinib ToxicityJournal of Clinical Oncology, 2008
- Lung cancer in never smokers — a different diseaseNature Reviews Cancer, 2007
- CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutationNature Clinical Practice Oncology, 2007
- Phase II Clinical Trial of Chemotherapy-Naïve Patients ≥ 70 Years of Age Treated With Erlotinib for Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2007
- Lung Cancer in Never Smokers: A ReviewJournal of Clinical Oncology, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Predictors of the Response to Gefitinib in Refractory Non–Small Cell Lung CancerClinical Cancer Research, 2005
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Primary lung cancer in Mexico city: a report of 1019 casesLung Cancer, 1996